Clinical Report: Advancing beyond mere quantification in transcriptomics
Overview
Single-cell long-read sequencing (scLRS) offers advancements in understanding the complexities of the cancer transcriptome by enabling the sequencing of full-length RNA molecules.
Background
The limitations of short-read single-cell RNA sequencing (scRNA-seq) restrict the understanding of the full transcriptomic landscape, which is crucial for developing effective cancer therapies. Tumor heterogeneity and genetic diversity complicate treatment strategies.
Data Highlights
No numerical data available in the source material.
Key Findings
scLRS can sequence full-length RNA molecules, overcoming limitations of short-read platforms.
This technology aids in identifying novel tumor-specific neo-antigens and fusion genes.
Linking genotype information with transcript expression can lead to isoform-selective therapies.
scLRS enables tracing of tumor clone subtypes and clonal evolution through SNV variation.
Current challenges include cost, throughput, and the need for standardized bioinformatic tools.
Clinical Implications
Understanding the transcriptomic complexity at the single-cell level may enhance the ability to address tumor heterogeneity.
Conclusion
As technological and computational challenges are addressed, scLRS is a tool in precision oncology.
